Theriva BiologicsTOVX +1.74%26 PS Ratio is 34.21 as of Jul. 08, 2026, which is 7% below its 10-year median of 36.74. GuruFocus rates TOVX with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 928 Biotechnology companies, Theriva Biologics ranks worse than 74.25% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Theriva Biologics's share price is $0.2395.
Theriva Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01. Hence, Theriva Biologics's PS Ratio for today is 34.21.
Good Sign:
Theriva Biologics Inc stock PS Ratio (=33.63) is close to 1-year low of 32.84.
The historical rank and industry rank for Theriva Biologics's PS Ratio or its related term are showing as below:
TOVX'
s PS Ratio Range Over the Past 10 Years
Min: 32.49 Med: 36.74 Max: 55.66
Current: 34.21
During the past 13 years, Theriva Biologics's highest PS Ratio was 55.66. The lowest was 32.49. And the median was 36.74.
TOVX's PS Ratio is ranked worse than 74.25% of 928
companies
in the Biotechnology industry
Industry Median: 9.59
vs TOVX: 34.21
Theriva Biologics (AMEX:TOVX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Theriva Biologics PS Ratio Related Terms
Theriva Biologics PS Ratio Historical Data
* Premium members only.
The historical data trend for Theriva Biologics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Theriva Biologics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theriva Biologics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theriva Biologics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Theriva Biologics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Theriva Biologics's Share Price of today is $0.2395. Theriva Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Theriva Biologics (TOVX) has a PS Ratio of 34.21 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Theriva Biologics and its competitors. This is near median its historical median of 36.74. Over the past decade, Theriva Biologics' PS Ratio has ranged from 32.49 to 55.66. According to the industry distribution chart, Theriva Biologics ranks #689 out of 928 companies in the Biotechnology industry, placing it in the top 74.2%.
Is Theriva Biologics' PS Ratio too high?
Theriva Biologics' current PS Ratio of 34.21 is near median its 10-year median of 36.74. Over the past 10 years, this metric has ranged from a low of 32.49 to a high of 55.66. The Biotechnology industry median PS Ratio is 9.59. Theriva Biologics' value of 34.21 is 256.7% above this industry median. Based on the distribution chart, Theriva Biologics ranks #689 out of 928 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Theriva Biologics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Theriva Biologics' PS Ratio compare to OSRH and PBM?
According to the Biotechnology industry distribution chart, Theriva Biologics ranks #689 out of 928 companies for PS Ratio. This places Theriva Biologics in the lower half of its industry. The industry median PS Ratio is 9.59. Theriva Biologics' value of 34.21 is 256.7% above this benchmark. Historically, Theriva Biologics' own PS Ratio has ranged from 32.49 to 55.66 over the past decade. While the company's 10-year median is 36.74 vs. the industry median of 9.59, Theriva Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.59, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theriva Biologics's current PS Ratio of 34.21 is 256.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Theriva Biologics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theriva Biologics's current PS Ratio is 34.21, which is near median its own 10-year median of 36.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theriva Biologics stock overvalued right now?
Theriva Biologics (TOVX) has a current PS Ratio of 34.21. The current PS Ratio is 34.21, which is near median its 10-year median of 36.74 and 256.7% above the Biotechnology industry median of 9.59. Theriva Biologics' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Theriva Biologics (TOVX), the current PS Ratio is 34.21 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
26GF Score
Get the complete analysis for TOVX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOVX has been successfully added to your 
